以吉瑞替尼为基础的联合方案治疗成人复发/难治性FLT3突变急性髓系白血病
回顾性分析33例复发/难治性FLT3突变急性髓系白血病患者,比较吉瑞替尼联合去甲基化药物及维奈克拉(G+HMA+VEN)、吉瑞替尼联合去甲基化药物(G+HMA)、吉瑞替尼联合维奈克拉(G+VEN)的疗效与安全性。G+HMA+VEN组的复合完全缓解率(CRc)和改良复合完全缓解率(mCRc)分别为66.7%(12/18)和88.9%(16/18),高于G+HMA组(CRc 18.2%,2/11;mCRc 45.5%,5/11)和G+VEN组(CRc 50.0%,2/4;mCRc 50.0%,2/4)。
要点
- G+HMA+VEN组CRc为66.7%(12/18),mCRc为88.9%(16/18)。
- G+HMA+VEN组中位总生存期未达到,G+HMA组为160.0天,G+VEN组为231.0天。
- G+HMA+VEN组中位缓解持续时间未达到,G+HMA组为82.0天,G+VEN组为77.0天。
核心结论
- 以吉瑞替尼为基础的联合方案在复发/难治性FLT3突变急性髓系白血病中显示出疗效,G+HMA+VEN组合可能被视为一种有效的移植桥接治疗。
研究设计与样本
- 回顾性分析33例复发/难治性FLT3突变急性髓系白血病患者,比较G+HMA+VEN、G+HMA和G+VEN三种联合方案的疗效与安全性。
主要发现
- G+HMA+VEN组CRc为66.7%(12/18),mCRc为88.9%(16/18);G+HMA组CRc为18.2%(2/11),mCRc为45.5%(5/11);G+VEN组CRc为50.0%(2/4),mCRc为50.0%(2/4)。
- G+HMA+VEN组中位总生存期未达到,G+HMA组为160.0天,G+VEN组为231.0天。
- G+HMA+VEN组中位缓解持续时间未达到,G+HMA组为82.0天,G+VEN组为77.0天。
- G+HMA+VEN组中4例患者在缓解后接受异基因造血干细胞移植,中位缓解持续时间延长。
- 最常见的3/4级不良事件为血细胞减少、发热性中性粒细胞减少和肺部感染,三组间无差异。
临床怎么用
- 作者认为,G+HMA+VEN联合方案在复发/难治性FLT3突变急性髓系白血病中显示出有前景的缓解,可考虑作为移植桥接的有效治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gilteritinib, a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor, was approved for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukaemia (AML) patients but still showed limited efficacy. Here, we retrospectively analysed the efficacy and safety of different gilteritinib-based combination therapies (gilteritinib plus hypomethylating agent and venetoclax, G + HMA + VEN; gilteritinib plus HMA, G + HMA; gilteritinib plus venetoclax, G + VEN) in 33 R/R FLT3-mutated AML patients. The composite complete response (CRc) and modified CRc (mCRc) rates were 66.7% (12/18) and 88.9% (16/18) in patients received G + HMA + VEN, which was higher compared with that in G + HMA (CRc: 18.2%, 2/11; mCRc: 45.5%, 5/11) or G + VEN (CRc: 50.0%, 2/4; mCRc: 50.0%, 2/4). The median overall survival (OS) for G + HMA + VEN, G + HMA and G + VEN treatment was not reached, 160.0 days and 231.0 days. The median duration of remission (DOR) for G + HMA + VEN, G + HMA and G + VEN treatment was not reached, 82.0 days and 77.0 days. Four patients in the G + HMA + VEN group received alloHSCT after remission exhibited prolonged median DOR. The most common grade 3/4 adverse events were cytopenia, febrile neutropenia and pulmonary infection; there were no differences among the three groups. In conclusion, our data demonstrated promising response of G + HMA + VEN combination therapy in R/R FLT3-mutated AML, and it may be considered an effective therapy bridge to transplantation.
引用
- Chen N, Pan J, Zhou Y, et al. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia. Br J Haematol. 2023. PMID: 37939390. doi:10.1111/bjh.19182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。